SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
1 Year Est. Return
+115.63%
AUM
$2.47B
AUM Growth
+$112M
(+4.7%)
Holding
119
Top Buys
| 1 | +$104M | |
| 2 | +$63.4M | |
| 3 | +$63.3M | |
| 4 |
Krystal Biotech
KRYS
|
+$56.4M |
| 5 |
Progyny
PGNY
|
+$44.3M |
Top Sells
| 1 | +$80.6M | |
| 2 | +$74.2M | |
| 3 | +$57.1M | |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$39M |
| 5 |
GSK
GSK
|
+$31.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Kiniksa Pharmaceuticals
KNSA
$3.79B
| $25.1M | 1.02% |
521,353
-65,647
|
|
||
27
Merck
MRK
$283B
| $24.4M | 0.99% |
+203,000
|
|
||
28
Organogenesis Holdings
ORGO
$300M
| $23.9M | 0.97% |
10,085,951
+100,000
|
|
||
29
Natera
NTRA
$30.3B
| $23.8M | 0.96% |
119,000
+99,000
|
|
||
30
Axogen
AXGN
$2.16B
| $22.5M | 0.91% |
679,170
-527,685
|
|
||
31
Vaxcyte
PCVX
$6.78B
| $22.4M | 0.91% |
385,472
-223,486
|
|
||
32
Icon
ICLR
$11B
| $21.2M | 0.86% |
+192,000
|
|
||
33
Pharvaris
PHVS
$2.11B
| $19.8M | 0.8% |
702,052
|
|
||
34
Cerus
CERS
$533M
| $19.6M | 0.79% |
10,753,700
+6,753,700
|
|
||
35
Trevi Therapeutics
TRVI
$1.91B
| $19.3M | 0.78% |
1,620,000
+720,000
|
|
||
36
Inhibikase Therapeutics
IKT
$220M
| $18.3M | 0.74% |
10,875,000
|
|
||
37
Context Therapeutics
CNTX
$187M
| $18.2M | 0.74% |
+6,963,141
|
|
||
38
Vir Biotechnology
VIR
$1.54B
| $17.9M | 0.73% |
+2,002,000
|
|
||
39
Xenon Pharmaceuticals
XENE
$5.12B
| $17M | 0.69% |
+292,000
|
|
||
40
Travere Therapeutics
TVTX
$4.2B
| $16.2M | 0.66% |
+546,000
|
|
||
41
Tandem Diabetes Care
TNDM
$1.24B
| $15M | 0.61% |
+783,000
|
|
||
42
Nurix Therapeutics
NRIX
$1.6B
| $14.5M | 0.59% |
938,163
-281,231
|
|
||
43
UroGen Pharma
URGN
$1.3B
| $13.1M | 0.53% |
727,000
+577,000
|
|
||
|
SION
44
Sionna Therapeutics
SION
$1.66B
| $11.8M | 0.48% |
293,500
+25,000
|
|
||
45
Corcept Therapeutics
CORT
$7.8B
| $11.5M | 0.47% |
+285,531
|
|
||
|
JBIO
46
Jade Biosciences
JBIO
$868M
| $11.2M | 0.45% |
796,744
|
|
||
47
Veracyte
VCYT
$3.89B
| $10.3M | 0.42% |
319,912
+309,912
|
|
||
48
Invivyd
IVVD
$327M
| $10M | 0.41% |
7,708,727
|
|
||
49
C4 Therapeutics
CCCC
$461M
| $10M | 0.41% |
3,803,942
|
|
||
50
OrthoPediatrics
KIDS
$435M
| $9.77M | 0.4% |
615,447
+90,000
|
|